La Jolla Pharmaceutical Company (LJPC) stock price, revenue, and financials

La Jolla Pharmaceutical Company market cap is $116.2 m, and annual revenue was $33.42 m in FY 2020

$116.2 M

LJPC Mkt cap, 09-Sept-2021

$16.1 M

La Jolla Pharmaceutical Company Revenue Q2, 2021
La Jolla Pharmaceutical Company Net income (Q2, 2021)3.7 M
La Jolla Pharmaceutical Company EBIT (Q2, 2021)3.8 M
La Jolla Pharmaceutical Company Cash, 30-Jun-202145.9 M
La Jolla Pharmaceutical Company EV70.7 M
Get notified regarding key financial metrics and revenue changes at La Jolla Pharmaceutical CompanyLearn more
Banner background

La Jolla Pharmaceutical Company Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.1m616.0k10.1m23.1m33.4m

Cost of goods sold

1.6m2.4m7.8m

Gross profit

8.4m20.7m25.6m

Gross profit Margin, %

84%90%77%

R&D expense

177.0k1.4m4.4m9.9m29.1m62.3m84.6m117.3m85.3m23.0m

General and administrative expense

2.1m9.4m13.6m11.4m13.9m16.7m30.9m85.2m45.1m38.4m

Operating expense total

2.3m10.7m17.9m21.3m43.0m79.0m115.4m202.5m130.5m61.4m

EBIT

(2.3m)(10.7m)(17.9m)(21.3m)(42.0m)(78.4m)(115.4m)(194.1m)(109.8m)(35.8m)

EBIT margin, %

(3971%)(12723%)(1930%)(476%)(107%)

Interest expense

6.7m3.6m

Interest income

1.9m2.1m235.0k

Income tax expense

Net Income

(11.5m)(7.7m)(17.9m)(21.3m)(41.9m)(78.2m)(114.8m)(199.5m)(116.5m)(39.4m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q2, 2021

Revenue

647.0k234.0k253.0k44.0k809.0k1.6m3.5m4.4m5.7m5.7m7.6m5.8m16.1m

Cost of goods sold

58.0k129.0k256.0k500.0k551.0k554.0k716.0k808.0k

Gross profit

751.0k1.5m3.2m3.9m5.2m5.2m6.9m5.0m

Gross profit Margin, %

93%92%93%89%90%90%91%86%

R&D expense

177.0k34.0k474.0k655.0k700.0k948.0k2.0m1.6m2.6m5.2m6.7m7.8m12.7m12.4m17.0m17.8m20.8m19.1m28.4m30.9m30.4m21.2m22.0m21.2m9.2m8.8m1.1m

General and administrative expense

727.0k423.0k637.0k3.0m3.5m2.5m3.2m3.1m2.7m2.4m3.8m4.0m3.4m4.1m3.5m4.3m5.5m6.0m7.4m23.0m22.2m21.1m12.3m11.3m10.8m8.2m8.7m9.0m

Operating expense total

904.0k423.0k671.0k3.4m4.2m3.2m4.2m5.1m4.3m5.1m9.0m10.7m11.1m16.7m15.9m21.3m23.3m26.8m26.5m51.4m53.0m51.6m33.6m33.4m32.0m17.3m17.5m10.1m

EBIT

(904.0k)(423.0k)(671.0k)(3.4m)(4.2m)(3.2m)(4.2m)(5.1m)(4.3m)(5.1m)(9.0m)(10.7m)(10.5m)(16.5m)(15.6m)(21.3m)(23.3m)(26.8m)(26.5m)(50.7m)(51.6m)(48.4m)(29.7m)(28.2m)(26.8m)(10.5m)(12.5m)3.8m

EBIT margin, %

(1621%)(7057%)(6173%)(48402%)(6266%)(3237%)(1394%)(675%)(495%)(470%)(138%)(215%)24%

Interest expense

1.2m2.4m2.0m2.2m2.4m1.9m3.1m60.0k

Interest income

713.0k604.0k501.0k190.0k32.0k

Pre tax profit

3.7m

Income tax expense

Net Income

4.7m3.6m5.3m(2.2m)(4.2m)(3.2m)(4.2m)(5.1m)(4.3m)(5.1m)(9.0m)(10.6m)(10.5m)(16.5m)(15.6m)(21.3m)(23.2m)(26.7m)(26.3m)(50.5m)(52.8m)(50.7m)(31.7m)(30.4m)(29.2m)(8.6m)(15.6m)3.7m

La Jolla Pharmaceutical Company Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q2, 2021

Cash

5.8m5.5m4.4m3.8m3.4m2.7m1.8m10.7m5.9m3.9m54.1m42.7m36.0m135.1m113.1m100.6m85.0m162.4m141.3m120.8m154.4m241.4m204.3m140.0m123.4m104.8m77.2m68.4m45.9m

Accounts Receivable

372.0k1.5m2.0m1.9m1.4m3.6m1.8m8.6m

Prepaid Expenses

19.0k9.0k50.0k97.0k40.0k76.0k67.0k47.0k156.0k148.0k153.0k622.0k622.0k484.0k1.4m1.4m1.4m1.7m1.8m1.8m6.3m5.3m5.8m5.1m5.1m4.8m3.4m2.8m5.2m

Inventories

820.0k2.0m2.0m1.9m2.0m3.1m5.5m

Current Assets

5.8m5.5m4.4m3.9m3.4m2.8m1.9m10.8m6.1m4.1m54.3m44.8m37.2m136.1m114.7m102.3m86.7m164.4m144.0m123.5m161.6m248.0m212.8m149.1m132.4m112.9m86.1m79.2m65.2m

PP&E

37.0k37.0k51.0k89.0k114.0k659.0k1.5m1.8m2.0m2.3m2.6m3.6m4.6m6.5m24.4m24.2m23.3m21.3m20.4m19.5m16.0m12.8m163.0k

Goodwill

20.1m

Total Assets

5.8m5.5m4.4m3.9m3.4m2.8m2.0m10.8m6.1m4.2m54.4m45.5m38.7m137.9m117.0m104.8m89.5m168.0m148.6m130.1m186.9m273.1m237.1m187.8m169.9m149.1m118.2m107.4m100.0m

Accounts Payable

26.0k23.0k36.0k129.0k68.0k69.0k176.0k473.0k562.0k917.0k683.0k2.5m1.8m2.6m2.4m2.3m2.0m4.2m5.9m6.2m7.3m6.1m6.6m3.0m4.9m5.3m1.9m2.5m1.8m

Short-term debt

2.8m2.9m168.0k

Current Liabilities

6.9m2.6m9.7m14.0m12.9m271.0k308.0k577.0k906.0k1.1m1.6m2.6m2.5m4.3m5.2m5.2m7.2m5.7m8.3m10.3m16.0m19.0m23.9m17.2m22.0m22.5m16.0m17.9m16.1m

Long-term debt

28.6m27.9m27.2m25.7m25.0m251.0k

Total Debt

28.6m27.9m27.2m28.6m27.9m419.0k

Total Liabilities

29.5m157.5m162.1m176.5m182.5m184.3m179.9m182.6m167.5m

Common Stock

3.0k6.0k4.0k5.0k5.0k2.0k3.0k21.0k4.0k4.0k4.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k

Preferred Stock

3.6m3.6m3.6m

Additional Paid-in Capital

423.5m424.0m420.2m422.7m425.3m443.2m445.1m458.8m467.2m471.1m525.9m531.9m535.8m643.7m650.2m653.5m657.5m785.6m790.4m796.1m922.8m933.8m943.9m959.9m966.4m973.0m980.3m982.4m987.2m

Retained Earnings

(429.9m)(426.3m)(434.3m)(442.0m)(444.3m)(451.6m)(454.7m)(458.9m)(470.4m)(474.7m)(479.8m)(495.6m)(506.2m)(516.7m)(545.0m)(560.6m)(581.8m)(630.0m)(656.7m)(683.0m)(772.0m)(824.8m)(875.6m)(952.5m)(982.9m)(1.0b)(1.0b)(1.1b)(1.1b)

Total Equity

(6.4m)(2.3m)(10.6m)(15.7m)(15.3m)2.5m1.7m10.2m5.2m3.1m52.8m43.0m36.2m133.6m111.8m99.6m82.3m162.3m140.3m119.8m157.4m115.7m75.0m11.3m(12.6m)(35.2m)(61.7m)(75.2m)(67.4m)

Financial Leverage

-0.9 x-2.4 x-0.4 x-0.2 x-0.2 x1.1 x1.2 x1.1 x1.2 x1.3 x1 x1.1 x1.1 x1 x1 x1.1 x1.1 x1 x1.1 x1.1 x1.2 x2.4 x3.2 x16.6 x-13.5 x-4.2 x-1.9 x-1.4 x-1.5 x

La Jolla Pharmaceutical Company Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q2, 2021

Net Income

(1.8m)1.8m5.3m(2.4m)(4.6m)(4.2m)(7.4m)(11.5m)(5.1m)(9.4m)(14.5m)(9.0m)(19.6m)(30.1m)(16.5m)(32.0m)(53.3m)(23.2m)(50.0m)(76.3m)(50.5m)(103.3m)(154.1m)(31.7m)(62.1m)(91.3m)(8.6m)(24.2m)18.2m

Depreciation and Amortization

1.0k3.0k2.0k5.0k10.0k11.0k95.0k209.0k142.0k310.0k510.0k281.0k581.0k899.0k992.0k2.1m3.2m1.1m2.3m3.4m1.1m1.8m56.0k

Accounts Receivable

(372.0k)(1.5m)(618.0k)(512.0k)(36.0k)(592.0k)1.1m(2.8m)

Inventories

43.0k52.0k110.0k251.0k(909.0k)(318.0k)

Accounts Payable

(92.0k)(43.0k)28.0k121.0k60.0k46.0k68.0k322.0k(197.0k)(46.0k)562.0k1.7m1.1m1.8m(98.0k)(250.0k)(508.0k)(2.5m)(732.0k)(413.0k)(4.2m)(5.4m)(4.9m)(5.5m)(3.7m)(3.2m)(2.3m)(1.7m)(920.0k)

Cash From Operating Activities

(1.1m)(1.4m)(659.0k)(1.2m)(1.7m)(705.0k)(1.5m)(2.6m)(2.7m)(4.7m)(7.5m)(5.5m)(11.2m)(16.7m)(13.0m)(25.1m)(40.1m)(22.1m)(41.9m)(60.4m)(45.8m)(83.4m)(120.3m)(32.7m)(49.2m)(67.8m)(12.2m)(20.6m)24.3m

Purchases of PP&E

(38.0k)(40.0k)(15.0k)(56.0k)(86.0k)(391.0k)(1.3m)(1.7m)(478.0k)(910.0k)(1.4m)(750.0k)(2.0m)(4.3m)(994.0k)(1.9m)(2.3m)(184.0k)(441.0k)(679.0k)

Cash From Investing Activities

(38.0k)(77.0k)(15.0k)(56.0k)(86.0k)(391.0k)(1.3m)(1.7m)(478.0k)(910.0k)(1.4m)(750.0k)(2.0m)(4.3m)(994.0k)(1.9m)(2.3m)(184.0k)(441.0k)(679.0k)1.1m(139.0k)

Dividends Paid

(374.0k)374.0k

Cash From Financing Activities

10.0m53.1m57.0k57.0k104.9m85.0k85.0k85.0k119.6m119.6m119.8m110.3m235.8m236.0m283.0k484.0k661.0k505.0k964.0k353.0k

Net Change in Cash

(1.1m)(1.4m)(659.0k)(1.2m)(1.7m)(705.0k)(1.6m)7.3m(2.7m)(4.7m)45.5m(5.8m)(12.5m)86.5m(13.4m)(25.9m)(41.4m)96.7m75.6m55.1m63.5m150.5m113.4m(32.6m)(49.2m)(67.8m)(10.6m)(19.8m)24.7m

La Jolla Pharmaceutical Company Ratios

USDQ2, 2011

Financial Leverage

-0.9 x